Rethinking treatment of acne in the severe patient

Journal of Drugs in Dermatology

Volumn 10, Issue 6, 2011, Pages

  Thiboutot, Diane ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANTIBIOTIC AGENT; BENZOYL PEROXIDE; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; MINOCYCLINE; PLACEBO; RETINOID; TAZAROTENE; TETRACYCLINE;

ACNE; ACNE VULGARIS; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; HUMAN; REVIEW; TOPICAL TREATMENT; TREATMENT RESPONSE;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ALGORITHMS; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; RETINOIDS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 80053089900     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(suppl 5):1S-50S.
2. Del Rosso JQ, Leyden JJ, Thiboutot D, et al. Antibiotic use in acne vulgaris and rosacea: Clinical considerations and resistance issues of significance to dermatologists. Cutis. 2008;82(2 suppl 2):5-12.
3. Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14(6):391-399. (Pubitemid 39551602)
4. Liu PT, Krutzik SR, Kim J, et al. Cutting edge: All-trans retinoic acid down-regulates TLR2 expression and function. J Immunol. 2005;174(5):2467-2470. (Pubitemid 40279655)
5. Gold LS, Tan J, Cruz-Santana A, et al. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis. 2009;84(2):110-116.
6. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: A multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63(6):349-354.
7. Leyden JJ, Shalita A, Thiboutot D, et al. Topical retinoids in inflammatory acne: A retrospective, investigator-blinded, vehicle-controlled, photographic assessment. Clin Ther. 2005;27(2):216-224. (Pubitemid 40462015)
8. Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006;54(2):242-250. (Pubitemid 43144393)
9. Berger R, Barba A, Fleischer A, et al. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis. 2007;80(2):152-157.
10. Thiboutot D, Eichenfield L, Shalita A, et al. A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide. Cutis. 2009;84(1):48-55.
11. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439 e1-10. Epub January 17, 2007.
12. Leyden J, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: A multicenter, double-blind, randomized, parallel-group study. Arch Dermatol. 2006;142(5):605-612. (Pubitemid 43727551)
13. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: A multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005;4(3):138-146.
14. Gold LS, Cruz A, Eichenfield L, et al. Effective and safe combination therapy for severe acne vulgaris: A randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis. 2010;85(2):94-104.
15. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: A randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006;142(5):597-602. (Pubitemid 43727550)
16. Dreno B, Thiboutot D, Gollnick H, et al. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol; 49(4):448-456.
17. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651-663. (Pubitemid 46400177)
18. Eady E, Jones C, Tipper J, et al. Antibiotic resistant propionibacteria in acne: Need for policies to modify antibiotic usage. Br Med J. 1993;306:555-556. (Pubitemid 23056875)
19. Bojar R, Eady E, Jones C, et al. Inibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol. 1994;130(3):329-336. (Pubitemid 24204642)
20. Coates P, Vyakrnam S, Eady E, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol. 2002;146:840-848. (Pubitemid 34539195)
21. Eady E, Jones C, Gardner K, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br J Dermatol. 1993;128:556-560. (Pubitemid 23155955)